211 related articles for article (PubMed ID: 21357659)
1. Functional and biochemical rationales for the 24-hour-long duration of action of olodaterol.
Casarosa P; Kollak I; Kiechle T; Ostermann A; Schnapp A; Kiesling R; Pieper M; Sieger P; Gantner F
J Pharmacol Exp Ther; 2011 Jun; 337(3):600-9. PubMed ID: 21357659
[TBL] [Abstract][Full Text] [Related]
2. A randomised, placebo-controlled, Phase II, dose-ranging trial of once-daily treatment with olodaterol, a novel long-acting β2-agonist, for 4 weeks in patients with chronic obstructive pulmonary disease.
Maleki-Yazdi MR; Beck E; Hamilton AL; Korducki L; Koker P; Fogarty C
Respir Med; 2015 May; 109(5):596-605. PubMed ID: 25829298
[TBL] [Abstract][Full Text] [Related]
3. Pharmacological characterization of olodaterol, a novel inhaled beta2-adrenoceptor agonist exerting a 24-hour-long duration of action in preclinical models.
Bouyssou T; Casarosa P; Naline E; Pestel S; Konetzki I; Devillier P; Schnapp A
J Pharmacol Exp Ther; 2010 Jul; 334(1):53-62. PubMed ID: 20371707
[TBL] [Abstract][Full Text] [Related]
4. In vitro pharmacological characterization of vilanterol, a novel long-acting β2-adrenoceptor agonist with 24-hour duration of action.
Slack RJ; Barrett VJ; Morrison VS; Sturton RG; Emmons AJ; Ford AJ; Knowles RG
J Pharmacol Exp Ther; 2013 Jan; 344(1):218-30. PubMed ID: 23131596
[TBL] [Abstract][Full Text] [Related]
5. Pharmacological characterization of abediterol, a novel inhaled β(2)-adrenoceptor agonist with long duration of action and a favorable safety profile in preclinical models.
Aparici M; Gómez-Angelats M; Vilella D; Otal R; Carcasona C; Viñals M; Ramos I; Gavaldà A; De Alba J; Gras J; Cortijo J; Morcillo E; Puig C; Ryder H; Beleta J; Miralpeix M
J Pharmacol Exp Ther; 2012 Aug; 342(2):497-509. PubMed ID: 22588259
[TBL] [Abstract][Full Text] [Related]
6. A randomised, double-blind, four-way, crossover trial comparing the 24-h FEV1 profile for once-daily versus twice-daily treatment with olodaterol, a novel long-acting β2-agonist, in patients with chronic obstructive pulmonary disease.
Joos GF; Aumann JL; Coeck C; Korducki L; Hamilton AL; Kunz C; Aalbers R
Respir Med; 2015 May; 109(5):606-15. PubMed ID: 25776199
[TBL] [Abstract][Full Text] [Related]
7. In vitro and in vivo preclinical profile of abediterol (LAS100977), an inhaled long-acting β2-adrenoceptor agonist, compared with indacaterol, olodaterol and vilanterol.
Aparici M; Gavaldà A; Ramos I; Carcasona C; Otal R; Fernández-Blanco JA; Montero JL; García VM; López R; De Alba J; Doe C; Puig C; Vilella D; Miralpeix M
Eur J Pharmacol; 2016 Jan; 770():61-9. PubMed ID: 26656755
[TBL] [Abstract][Full Text] [Related]
8. Characteristics of AZD9708, a novel, selective β2-adrenoceptor agonist with rapid onset and long duration of action.
Nicholls DJ; Jordan S; Cadogan E; Lawson M; Austin RP; Paine SW; Gardiner P; Bonnert R; Connolly S; Young A
Pulm Pharmacol Ther; 2012 Aug; 25(4):293-302. PubMed ID: 22659538
[TBL] [Abstract][Full Text] [Related]
9. Olodaterol for the treatment of chronic obstructive pulmonary disease: a narrative review.
Melani AS
Expert Opin Pharmacother; 2018 Oct; 19(14):1603-1611. PubMed ID: 30311516
[TBL] [Abstract][Full Text] [Related]
10. Effect of long-acting beta-agonists on the frequency of COPD exacerbations: a meta-analysis.
Wang J; Nie B; Xiong W; Xu Y
J Clin Pharm Ther; 2012 Apr; 37(2):204-11. PubMed ID: 21740451
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic potential for novel ultra long-acting β2-agonists in the management of COPD: biological and pharmacological aspects.
Malerba M; Radaeli A; Morjaria JB
Drug Discov Today; 2012 May; 17(9-10):496-504. PubMed ID: 22119310
[TBL] [Abstract][Full Text] [Related]
12. [Long-acting beta-2-agonists in the treatment of asthma].
Rochat T
Schweiz Med Wochenschr; 1994 Oct; 124(39):1714-9. PubMed ID: 7939538
[TBL] [Abstract][Full Text] [Related]
13. Corticosteroids and adrenoceptor agonists: the compliments for combination therapy in chronic airways diseases.
Sin DD; Man SF
Eur J Pharmacol; 2006 Mar; 533(1-3):28-35. PubMed ID: 16457807
[TBL] [Abstract][Full Text] [Related]
14. Salmeterol Xinafoate.
Anwar MM; El-Haggar RS; Zaghary WA
Profiles Drug Subst Excip Relat Methodol; 2015; 40():321-69. PubMed ID: 26051688
[TBL] [Abstract][Full Text] [Related]
15. Mono- and combination therapy of long-acting bronchodilators and inhaled corticosteroids in advanced COPD.
Ohar JA; Donohue JF
Semin Respir Crit Care Med; 2010 Jun; 31(3):321-33. PubMed ID: 20496301
[TBL] [Abstract][Full Text] [Related]
16. The reassertion profiles of long acting β2-adrenoceptor agonists in the guinea pig isolated trachea and human recombinant β2-adrenoceptor.
Patel S; Summerhill S; Stanley M; Perros-Huguet C; Trevethick MA
Pulm Pharmacol Ther; 2011 Apr; 24(2):247-55. PubMed ID: 21134482
[TBL] [Abstract][Full Text] [Related]
17. ▼Olodaterol--another LABA for COPD.
Drug Ther Bull; 2015 Apr; 53(4):42-5. PubMed ID: 25858815
[TBL] [Abstract][Full Text] [Related]
18. Stable activation and desensitization of beta 2-adrenergic receptor stimulation of adenylyl cyclase by salmeterol: evidence for quasi-irreversible binding to an exosite.
Clark RB; Allal C; Friedman J; Johnson M; Barber R
Mol Pharmacol; 1996 Jan; 49(1):182-9. PubMed ID: 8569705
[TBL] [Abstract][Full Text] [Related]
19. Pharmacology and therapeutics of bronchodilators.
Cazzola M; Page CP; Calzetta L; Matera MG
Pharmacol Rev; 2012 Jul; 64(3):450-504. PubMed ID: 22611179
[TBL] [Abstract][Full Text] [Related]
20. Bronchodilating drugs for chronic obstructive pulmonary disease: current status and future trends.
Montuschi P; Ciabattoni G
J Med Chem; 2015 May; 58(10):4131-64. PubMed ID: 25587755
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
